Rapid Acting Insulin Market to Reach $8,925 Million by 2027, Driven by Rising Diabetes Prevalence Worldwide

Allied Market Research has published a comprehensive report titled "Rapid Acting Insulin Market by Product Type, Indication, and Distribution Channel: Global Opportunity Analysis and Industry Forecast, 2020-2027." The report reveals that the global rapid acting insulin market was valued at $7,100 million in 2019 and is projected to reach $8,925 million by 2027, registering a CAGR of 4.1% during the forecast period.

Rapid acting insulin is among the fastest-acting insulin formulations available, beginning to work within 15 minutes of administration and lasting approximately 5 hours. Widely prescribed formulations in the market include Humalog, Fiasp, NovoRapid, and Apidra.

Download Sample Report at: https://www.alliedmarketresearch.com/request-sample/10964

Key Market Drivers

The global rapid acting insulin market is experiencing steady expansion, propelled by several macroeconomic and healthcare-related forces:

• Surge in diabetes prevalence: The worldwide rise in type 1 and type 2 diabetes cases is the primary growth driver for the market, creating sustained demand for insulin therapies.

• Increasing R&D investments: Significant investment in research and development of human recombinant insulin continues to expand treatment options and improve patient outcomes.

• Lifestyle-related diabetes risk: Sedentary lifestyles, unhealthy diets, and rising rates of obesity are estimated to account for approximately 80% of the growth in diabetes prevalence, directly fueling demand for rapid acting insulin.

• Government healthcare expenditure: Rising public healthcare spending globally is accelerating access to insulin therapies, particularly in emerging markets.

Market Restraints & Opportunities

Despite positive growth prospects, the market faces certain headwinds. Reluctance among patients to adopt rapid acting insulin - largely due to the risk of hypoglycemia - remains a notable restraint. However, undiagnosed and undertreated diabetic populations in developing regions present substantial untapped opportunities for market players seeking to expand their global footprint.

Impact of COVID-19

The COVID-19 pandemic introduced both challenges and growth opportunities for the rapid acting insulin market. While lockdowns disrupted supply chains and healthcare delivery globally, the pandemic also highlighted the elevated health risks faced by diabetic patients. According to the American Diabetes Association, people living with diabetes face a significantly higher risk of serious complications from COVID-19.

In response, leading pharmaceutical companies moved swiftly. In April 2020, Eli Lilly and Company launched its Lilly Insulin Value Program, enabling patients - regardless of insurance status - to fill monthly Lilly insulin prescriptions, including all Humalog formulations, for $35. Notably, no supply shortage of rapid acting insulin was reported during the pandemic period.

Market Segmentation Insights

By Product Type

The insulin lispro segment holds the largest market share and is anticipated to maintain its leadership throughout the forecast period. Key advantages of insulin lispro include faster subcutaneous absorption, an earlier and greater insulin peak, and a shorter duration of action - all of which contribute to improved blood glucose management. Other segments include insulin aspart and insulin glulisine.

By Indication

The type 2 diabetes segment dominates the market, reflecting global trends of rising urbanization, sedentary behavior, and unhealthy dietary habits. The type 1 diabetes segment, while smaller, represents a critical indication owing to the essential role of insulin in disease management.

By Distribution Channel

Drug stores and retail pharmacies account for the largest distribution channel segment, driven by their widespread availability and ability to offer alternative insulin options when specific prescribed brands are out of stock. Hospital pharmacies and online providers complete the distribution landscape.

Enquiry at: https://www.alliedmarketresearch.com/purchase-enquiry/10964

Regional Outlook

North America commanded the largest revenue share in 2019, a position it is expected to retain through 2027, supported by high rates of diabetes diagnosis, a growing geriatric population, and robust healthcare infrastructure.

Asia-Pacific is forecast to register the highest CAGR of 4.1% during the study period. Westernized lifestyle adoption, increasing obesity rates, a large and growing diabetic population, and favorable

government policies are key growth catalysts in the region. Europe, Latin America, the Middle East, and Africa also represent significant markets with improving healthcare access.

Competitive Landscape

The global rapid acting insulin market features a competitive mix of established pharmaceutical giants and emerging players. Key market participants include:

• Eli Lilly and Company

• Novo Nordisk A/S

• Sanofi S.A.

• Biocon Limited

• Mannkind Corporation

• Gan & Lee Pharmaceuticals

• ADOCIA SAS

• Geropharm LLC

• Wockhardt Ltd.

These organizations are leveraging strategic partnerships, innovative product launches, competitive pricing, and geographic expansion to strengthen their market positions.

Report Highlights at a Glance

Aspect Details

Market Value (2019) $7,100 Million

Projected Value (2027) $8,925 Million

CAGR (2020-2027) 4.1%

Base Year 2019

Forecast Period 2020-2027

Product Segments Insulin Lispro, Insulin Aspart, Insulin Glulisine

Indication Segments Type 1 Diabetes, Type 2 Diabetes

Distribution Channels Hospital Pharmacies, Drug Stores & Retail Pharmacies, Online Providers

Leading Region North America

Fastest Growing Region Asia-Pacific (CAGR: 4.1%)

Media Contact

David Correa Allied Market Research 5933 NE Win Sivers Drive #205, Portland, OR 97220 United States

USA/Canada (Toll Free): +1-800-792-5285

UK: +44-845-528-1300

India (Pune): +91-20-66346060

Email: help@alliedmarketresearch.com

Web: https://www.alliedmarketresearch.com

About Allied Market Research

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP, based in Portland, Oregon. AMR provides global enterprises and medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." The company's reports are targeted at key decision-makers, stakeholders, and industry participants, enabling them to navigate the complexities of the global business environment.

This release was published on openPR.